Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs
The results come two weeks after Pfizer slashed its full-year adjusted earnings and revenue guidance and launched a sweeping $3.5 billion cost-cutting plan.
Pfizer swings to quarterly loss due to Paxlovid write-off
Pfizer on Tuesday reported its first quarterly loss since 2019, as the U.S. drugmaker recorded $5.6 billion in charges related to its COVID products like its antiviral treatment Paxlovid and vaccin...
Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
Pfizer's combination flu and COVID vaccine candidates effective, trial data shows
Shares of Pfizer Inc (NYSE:PFE) and its German partner BioNTech rose after the two companies announced positive results from a Phase 1/2 study evaluating their combination vaccine candidates for CO...
Pfizer's combination Covid, flu vaccine will move to final-stage trial after positive data
Pfizer, Moderna and Novavax believe combination shots will simplify the process for people to protect themselves against Covid and the flu.
Pfizer's Dividend Yield Is Now 5%. Is the Stock a No-Brainer Buy for Income Investors?
The healthcare giant is struggling as demand drops for its COVID-19 products. The company projects that revenue could fall by as much as 42%.
A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free
Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. Roivant made $5 billion from the sale, after having only spent $15 million on development.
Pfizer (PFE) to Report Q3 Earnings: Here's What to Expect
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
Pfizer hopes to avoid scaring investors when it reports 3Q results on Halloween
Pfizer Inc (NYSE:PFE) is scheduled to report earnings on October 31 before the opening bell, but if past results are any indication, the pharmaceutical giant's earnings won't be spooky. The Street...
Roivant Sciences Sells Joint Venture With Pfizer to Roche for $7.1 Billion
London-based biotech firm Roivant Sciences (ROIV) agreed to sell its Telavant Holdings unit, which is co-owned by Pfizer (PFE), to Roche Holding for $7.1 billion.
Pfizer Stock: Interesting, If Discipline Returns
Pfizer Inc.'s acquisition of Seagen is the latest in a series of M&A deals fueled by pandemic-related profits. Despite the underperformance of Pfizer shares, the current share price shows potential...
Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion
Shares of Roivant Sciences Ltd. ROIV, -1.13% and Pfizer Inc. PFE, -1.73% gained ground premarket on Monday after Roche Holding AG RHHBY, +0.51% agreed to buy immunology company Telavant for $7.1 bi...
Pfizer Just Announced Layoffs. Should You Still Buy the Stock?
Pfizer is going to be trimming its headcount over the next 12 months. Its best-selling drugs of the last few years are no longer raking in lots of dough.
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
Pfizer's revenue has taken a big hit because of lower COVID-19-related sales. Roche just released third-quarter earnings.
Is Pfizer a Bad News Buy Right Now?
Pfizer recently cut its annual earnings guidance as demand for coronavirus products shrinks. Still, the company is in the middle of one of its most aggressive series of product launches ever -- aim...
Related Companies